IL142247A0 - Method of treating sickle cell disease and thalassemia - Google Patents

Method of treating sickle cell disease and thalassemia

Info

Publication number
IL142247A0
IL142247A0 IL14224799A IL14224799A IL142247A0 IL 142247 A0 IL142247 A0 IL 142247A0 IL 14224799 A IL14224799 A IL 14224799A IL 14224799 A IL14224799 A IL 14224799A IL 142247 A0 IL142247 A0 IL 142247A0
Authority
IL
Israel
Prior art keywords
thalassemia
sickle cell
cell disease
treating sickle
provides
Prior art date
Application number
IL14224799A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL142247A0 publication Critical patent/IL142247A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL14224799A 1998-11-23 1999-11-16 Method of treating sickle cell disease and thalassemia IL142247A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10947498P 1998-11-23 1998-11-23
PCT/US1999/026958 WO2000030676A1 (en) 1998-11-23 1999-11-16 Method of treating sickle cell disease and thalassemia

Publications (1)

Publication Number Publication Date
IL142247A0 true IL142247A0 (en) 2002-03-10

Family

ID=22327841

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14224799A IL142247A0 (en) 1998-11-23 1999-11-16 Method of treating sickle cell disease and thalassemia

Country Status (14)

Country Link
US (1) US6372213B2 (de)
EP (1) EP1133314B1 (de)
JP (1) JP2002530352A (de)
CN (1) CN1326357A (de)
AT (1) ATE232739T1 (de)
AU (1) AU1723200A (de)
BR (1) BR9915572A (de)
CA (1) CA2351591A1 (de)
DE (1) DE69905489T2 (de)
DK (1) DK1133314T3 (de)
ES (1) ES2192874T3 (de)
IL (1) IL142247A0 (de)
WO (1) WO2000030676A1 (de)
ZA (1) ZA200102727B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
EP2815749A1 (de) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
WO2018013693A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
WO2018013689A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
CN106399478B (zh) 2016-08-31 2024-09-03 桂林优利特医疗电子有限公司 一种荧光探针PCR法快速检测α/β-地中海贫血的试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
CZ298429B6 (cs) * 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
DE69905489D1 (de) 2003-03-27
EP1133314B1 (de) 2003-02-19
AU1723200A (en) 2000-06-13
BR9915572A (pt) 2001-08-14
US20020012662A1 (en) 2002-01-31
EP1133314A1 (de) 2001-09-19
DK1133314T3 (da) 2003-04-14
CA2351591A1 (en) 2000-06-02
CN1326357A (zh) 2001-12-12
ES2192874T3 (es) 2003-10-16
DE69905489T2 (de) 2003-09-11
JP2002530352A (ja) 2002-09-17
WO2000030676A1 (en) 2000-06-02
US6372213B2 (en) 2002-04-16
ZA200102727B (en) 2002-09-25
ATE232739T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
EP1537861A3 (de) Verwendung von Aminothiolverbindungen zur Behandlung von Xerostomie, verursacht durch therapeutische Mittel oder Bestrahlung
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
WO2002058684A3 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
CA2337991A1 (en) Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
WO2002034201A3 (fr) Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
IL142220A0 (en) Method of treating viral hemorrhagic fever
EP2241329A3 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
IL142247A0 (en) Method of treating sickle cell disease and thalassemia
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
IL140044A0 (en) Compounds with growth hormone releasing properties
GB9420747D0 (en) 1,5 benzodiazepine derivatives
IL142255A0 (en) Method of treating heparin-induced thrombocytopenia
WO1998023574A8 (en) Asiatic acid derivatives and medicines for treating wounds, which contains the same
AU5857899A (en) Use of tgf-beta inhibitors for treating cerebral disorders
UA42749C2 (uk) N,n-діетил-8,8-дипропіл-2-азаспіро[4,5]декан-2-пропанамін дималеат, фармацевтична композиція, спосіб лікування
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
IL142579A0 (en) Compounds with growth hormone releasing properties
CA2387394A1 (en) Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
WO2002046163A3 (de) Chinolin-derivative und ihre verwendung als antiepileptika
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
GB9818650D0 (en) Therapeutic compounds and methods of making and using the same